Foster Meredith C, Hwang Shih-Jen, Larson Martin G, Parikh Nisha I, Meigs James B, Vasan Ramachandran S, Wang Thomas J, Levy Daniel, Fox Caroline S
National Heart, Lung, and Blood Institute's Framingham Heart Study, 73 Mt Wayte Ave, Suite 2, Framingham, MA 01702, USA.
Arch Intern Med. 2007 Jul 9;167(13):1386-92. doi: 10.1001/archinte.167.13.1386.
Chronic kidney disease is defined by reduced estimated glomerular filtration rate (reduced eGFR) or by microalbuminuria (MA). Concordance between reduced eGFR and MA and associated cardiovascular disease (CVD) and all-cause mortality according to these definitions is uncertain.
Participants (n = 2966 [52.6% were women], mean age, 59 years) were drawn from the Framingham Offspring Cohort. Participants were classified into 4 groups based on the presence or absence of reduced eGFR (eGFR < 59 mL/min/1.73 m(2) in women, < 64 mL/min/1.73 m(2) in men or MA (spot urinary albumin to creatinine ratio of at least 30 mg/g). Cox proportional hazard models were used to determine the combined risk of CVD events and all-cause mortality for each group.
Of the participants, 9.9% (n = 295) had reduced eGFR, and 12.2% (n = 362) had MA. Among those with reduced eGFR, 28% had MA. Those with reduced eGFR and with MA were at increased risk for combined CVD and all-cause mortality compared with those with neither condition (hazard ratio [HR] 1.7, 95% confidence interval [CI], 1.1-2.4; P = .009), whereas those with reduced eGFR and without MA and those without reduced eGFR and with MA had similar HRs (1.3 and 1.2, respectively). Those with reduced eGFR and with MA, as well as those with reduced eGFR and without MA, were at significantly increased risk of all-cause mortality (HR 2.2 [95% CI, 1.4-3.6] and HR 1.7 [95% CI, 1.1-2.6], respectively).
Reduced eGFR and MA are relatively common conditions with different risk factor profiles. The coexistence of reduced eGFR and MA was present in 2.8% of the study sample and conferred substantial increased risk for CVD and all-cause mortality, in part because of a heavy burden of CVD risk factors.
慢性肾脏病的定义为估算肾小球滤过率降低(eGFR降低)或微量白蛋白尿(MA)。根据这些定义,eGFR降低与MA之间的一致性以及相关的心血管疾病(CVD)和全因死亡率尚不确定。
参与者(n = 2966 [52.6%为女性],平均年龄59岁)来自弗雷明汉后代队列。根据是否存在eGFR降低(女性eGFR<59 mL/min/1.73 m²,男性<64 mL/min/1.73 m²)或MA(随机尿白蛋白与肌酐比值至少为30 mg/g)将参与者分为4组。使用Cox比例风险模型确定每组发生CVD事件和全因死亡率的综合风险。
参与者中,9.9%(n = 295)eGFR降低,12.2%(n = 362)有MA。在eGFR降低的人群中,28%有MA。与两者均无的人群相比,eGFR降低且有MA的人群发生CVD和全因死亡率的综合风险增加(风险比[HR] 1.7,95%置信区间[CI],1.1 - 2.4;P = 0.009),而eGFR降低但无MA的人群和无eGFR降低但有MA的人群的HR相似(分别为1.3和1.2)。eGFR降低且有MA的人群以及eGFR降低但无MA的人群全因死亡率风险均显著增加(HR分别为2.2 [95% CI,1.4 - 3.6]和HR 1.7 [95% CI,1.1 - 2.6])。
eGFR降低和MA是相对常见的情况,具有不同的风险因素特征。eGFR降低和MA同时存在于2.8%的研究样本中,会使CVD和全因死亡率风险大幅增加,部分原因是CVD风险因素负担较重。